Evidence map›Paper›PMID 40663212›Full record

ArticleEJNMMI research2025

The effect of androgen blockade on [

Niels J van Ruitenbeek, Maike J M Uijen, Chantal M L Driessen, Maartje C van Rijk, Steffie M B Peters, Bastiaan M Privé, Gerald W Verhaegh, Adriana C H van Engen-van Grunsven, Martin Gotthardt, James Nagarajah and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04214353 (Effect of Androgen Deprivation Therapy on Uptake of PSMA Ligand in Patients With Salivary Duct Carcinoma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04214353 naunknown statusnot on this map

Effect of Androgen Deprivation Therapy on Uptake of PSMA Ligand in Patients With Salivary Duct Carcinoma: an Explorative Study.

TypeinterventionalSponsorRadboud University Medical CenterRan2020 to 2023Enrolled14ConditionsSalivary Gland Cancer, Salivary Duct CarcinomaArms68Ga-PSMA-PET/CT, 18FDG-PET/CT
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Niels J van RuitenbeekDepartment of Medical Oncology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA, Nijmegen, The Netherlands.
Maike J M UijenDepartment of Medical Oncology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA, Nijmegen, The Netherlands.
Chantal M L DriessenDepartment of Medical Oncology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA, Nijmegen, The Netherlands.
Maartje C van RijkDepartment of Medical Imaging, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Steffie M B PetersDepartment of Medical Imaging, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Bastiaan M PrivéDepartment of Medical Imaging, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Gerald W VerhaeghDepartment of Urology, Radboud Institute for Molecular Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Adriana C H van Engen-van GrunsvenDepartment of Pathology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Martin GotthardtDepartment of Medical Imaging, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
James NagarajahDepartment of Medical Imaging, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Carla M L van HerpenDepartment of Medical Oncology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA, Nijmegen, The Netherlands. Carla.vanHerpen@radboudumc.nl.ORCID http://orcid.org/0000-0001-5130-5451

Funding

KWF Kankerbestrijding 11807
6 · The paper itself

Abstract

backgroundThe expression of prostate-specific membrane antigen (PSMA), a target for oncological imaging and treatment, is upregulated by androgen blockade in prostate cancer. Salivary duct carcinoma (SDC), an aggressive histological subtype of salivary gland cancer, resembles prostate cancer in terms of PSMA and androgen receptor (AR) expression. A similar upregulation of PSMA in SDC would have implications for future studies with PSMA-targeted imaging and therapy. Additionally, FDG PET/CT scans are frequently used for SDC imaging, but the effect of androgen blockade on FDG uptake is unknown. This study investigated the effect of combined androgen blockade (CAB) on tumour PSMA and FDG uptake in patients with SDC.

resultsEight patients with recurrent and/or metastatic AR-positive SDC who started CAB (goserelin plus bicalutamide) as standard of care were prospectively enrolled. [

conclusionsAndrogen blockade in patients with recurrent and/or metastatic SDC did not induce a significant increase in tumour PSMA uptake after three weeks. In contrast, tumour FDG uptake increased significantly after three weeks of CAB, which may reflect the poor tumour response in this cohort and/or a transient treatment-related effect.

trial registrationClinicalTrials.gov, NCT04214353. Registered 13 December 2019.

Indexed as

[18F]FDGAndrogen deprivation therapyPositron emission tomographyProstate-specific membrane antigenSalivary duct carcinomaSalivary gland cancer

Identifiers

PMID40663212
PMCPMC12263521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.